Feasibility Study of Empagliflozin in Patients with Autosomal Dominant Polycystic Kidney Disease: Design and Baseline Characteristics
The outcomes of this pilot trial will provide important data regarding the safety and tolerability of empagliflozin in patients with ADPKD. Preliminary insight into the potential kidney and vascular benefits of SGLT2i will aid the design of future large-scale efficacy studies.
Authors
- Kristen L. Nowak (ORCID: https://orcid.org/0000-0001-9364-3256)
- Diana George
- Berenice Y. Gitomer (ORCID: https://orcid.org/0000-0002-7457-6497)
- Anna Ostrow
- Michel B. Chonchol
- C. L. Diggs
- Terry Watnick
- Stephen L. Seliger
- Wei Wang
- Zhiying You
- Miranda West
Institutions
- University of Maryland, Baltimore (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- American Journal of Nephrology
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1159/000549447
- Primary Topic
- Genetic and Kidney Cyst Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00